Check for updates

Outcomes for Pressure Ulcer Trials (OUTPUTs) project: review and classification of outcomes reported in pressure ulcer prevention research

A. Lechner ^(b), ¹ J. Kottner ^(b), ^{1,2} S. Coleman, ³ D. Muir, ³ D. Beeckman ^(b), ^{2,4,5,6} W. Chaboyer, ⁷ J. Cuddigan, ⁸ Z. Moore, ^{9,10,11,12,13} C. Rutherford, ^{14,15} J. Schmitt ^(b), ¹⁶ J. Nixon ^(b) ³ and K. Balzer^{3,17}

¹Charité – Universitätsmedizin Berlin, Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Berlin, Germany

²University Centre for Nursing and Midwifery, Ghent University, Ghent, Belgium

³Institute of Clinical Trials Research, Clinical Trials Research Unit, University of Leeds, Leeds, UK

⁴School of Health Sciences, Nursing and Midwifery, University of Surrey, Guildford, UK

⁵School of Nursing and Midwifery, Royal College of Surgeons in Ireland, Faculty of Medicine and Health Sciences, Dublin, Ireland

⁶School of Health Sciences, Örebro University, Örebro, Sweden

⁷School of Nursing and Midwifery, Menzies Health Institute Queensland, Griffith University and Gold Coast Hospital and Health Service, Southport, QLD, Australia

⁸University of Nebraska Medical Center, College of Nursing, Omaha, NE, USA

⁹Royal College of Surgeons in Ireland, Dublin, Ireland

¹⁰Monash University, Melbourne, VIC, Australia

¹¹Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

¹²Lida Institute, Shanghai, China

¹³Cardiff University, Cardiff, UK

¹⁴Faculty of Science, Quality of Life Office, School of Psychology, University of Sydney, Sydney, NSW, Australia

¹⁵Faculty of Medicine and Health, Susan Wakil School of Nursing and Midwifery, Cancer Nursing Research Unit (CNRU), University of Sydney, Sydney, NSW, Australia

¹⁶Centre for Evidence-based Healthcare, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany

¹⁷Institute for Social Medicine and Epidemiology, Nursing Research Unit, University of Lübeck, Lübeck, Germany

Linked Comment: Eleftheriadou. Br J Dermatol 2021; 184:587.

Correspondence

Anna Lechner. Email: anna.lechner@charite.de

Accepted for publication

3 June 2020

Funding sources

The University of Leeds (UK) and the European Pressure Ulcer Advisory Panel (EPUAP) provided financial support.

Conflicts of interest

The authors declare they have no conflicts of interest.

DOI 10.1111/bjd.19304

Summary

In order to overcome inconsistencies in the reporting of outcomes in clinical trials, core outcome sets (COSs) have been developed in many clinical areas and the awareness of this concept is growing steadily. The Outcomes for Pressure Ulcer Trials (OUTPUTs) project aims to improve the quality of evidence from pressure ulcer prevention trials by developing a COS. As an initial step in the COS process we aimed to identify and classify both outcomes and concepts that represent potential outcomes for future trials that have been reported in pressure ulcer prevention research. A review was conducted in 12 major databases covering the literature indexed until 2016. Outcomes and relevant concepts reported in primary studies and/or reviews on pressure ulcer prevention in adult patients were extracted as presented in the articles, and afterwards inductively grouped into outcome domains. The domains were then categorized according to the outcome domain taxonomy recently proposed by the COMET group. In total 332 studies were included and 68 outcome domains were identified, covering multiple aspects of pressure ulcer prevention. Pressure ulcer occurrence was reported in 71% of all included studies, representing the most frequent outcome, followed by costs (22% of all studies) and acceptability of intervention and comfort (18% of all studies). A plethora of different outcomes are applied in pressure ulcer prevention research and substantial variations in definitions and reporting of similar outcomes were observed. A COS for pressure ulcer prevention trials is needed to overcome the noncomparability of outcomes.

A pressure ulcer is defined as 'localized damage to the skin and/or underlying tissue, as a result of pressure or pressure in combination with shear'. Patients whose ability to move or position themselves is impaired are especially vulnerable to the development of pressure ulcers due to prolonged tissue exposure to pressure. Pressure ulcer prevention comprises different strategies (Figure 1).

Interventions aim to reduce the magnitude and duration of mechanical load such as pressure or shear forces, or intend to enhance tissue tolerance, for example by application of skincare products.^{1,2} Important efforts to establish and improve pressure ulcer prevention have been made in the past. Overall, the availability and quality of evidence to make recommendations for pressure ulcer prevention are weak.³ Thus, further research is necessary.^{4–6}

There are many clinical trials testing pressure ulcer prevention strategies. Unfortunately, there is also huge heterogeneity and inconsistency of outcomes used in pressure ulcer prevention trials. Outcomes are dependent variables measured during interventional studies and enable researchers to make statements about the effects, effectiveness and/or safety of interventions.⁷ The selection of patient-relevant and valid outcomes in clinical trials is crucial for the quality of study results.^{8,9} In order to generate meaningful evidence, it is also important that the study results of the same clinical area are comparable, as otherwise they cannot be summarized and pooled in systematic reviews or meta-analyses. 10

The incomparability of outcomes restricts evidence-based knowledge and aggravates decision making for clinicians in practice. To improve this situation, the concept of 'core outcome sets' (COSs) has been introduced and is promoted in many clinical areas now. A COS represents an agreed standardized set of outcomes that should be reported as a minimum in all clinical trials of a specific area (www.comet-initiative. org).¹¹ Developing a COS is a multistep consensus process that defines what to measure (core outcome domain set) and the measurement methods to quantify the determined core outcomes (core outcome measurement set). To date, no COS for pressure ulcer prevention trials exists. Thus, the 'Outcomes for Pressure Ulcer Trials project' (OUTPUTs project) has set the objective to develop a COS for this field following the latest methodological standards and recommendations.¹²⁻¹⁴ The aim is to develop a COS for the evaluation of the clinical efficacy, effectiveness and safety of pressure ulcer prevention strategies.

According to the Harmonising Outcome Measures for Eczema (HOME) roadmap,¹⁵ a suggested starting point for developing a COS is a list of all outcome domains ('long list').¹¹ Within this review, outcomes and outcome domains are regarded as synonyms because both are intended to measure the 'what' of outcomes. However, differences exist of



Figure 1 Conceptual scheme of pressure ulcer prevention.

how broadly or abstractly the outcome domains are defined.¹⁶ The aim of this research was to compile as comprehensive a list of outcome domains for clinical trials as possible. We sought to identify and classify both outcomes and concepts that represent potential outcomes for future trials that have been used and/or described in previous pressure ulcer prevention research literature.

Methods

A protocol describing the steps of the OUTPUTs project to develop a COS has been published.¹⁷ The OUTPUTs project is registered in the COMET database (http://www.comet-initia tive.org/studies/details/283) and is part of the Cochrane Skin Core Outcome Set Initiative (http://cs-cousin.org/outputs).

As one first step of this project, a scoping review was conducted to identify as many potential outcomes for pressure ulcer prevention trials as possible, including patient-reported outcomes (PROs), which are defined as outcomes that are directly reported by patients. Compared with a systematic review, a scoping review has less depth, but is favourable to get an overview of a broad topic and can cover a broader conceptual range.^{18,19} Unlike a systematic review this review did not aim to assess the 'weight' of evidence or appraise the methodological quality of studies, but aimed to provide a comprehensive overview of outcome domains.^{19–21}

Search strategy

Systematic searches were conducted between February and August 2016 in the following electronic databases: Cochrane Wounds Group/Cochrane Skin Group/Cochrane Wounds Group Specialised Register, Cochrane Central Register of Controlled Trials, Ovid MEDLINE, Ovid Embase, EBSCO CINAHL, PsychINFO, British Nursing Index, Allied and Complementary Medicine Database, Web of Knowledge, Clinical trials.gov and the WHO International Clinical Trials Registry Platform Search Portal. Database-specific search strategies were used covering the concept of 'pressure ulcer' (example in Appendix S1; see Supporting Information). The search strategies comprised controlled terms and free-text words retrieved from existing systematic reviews on pressure ulcer prevention efficacy.²²⁻²⁹ Electronic searches for evidence on PROs regarding pressure ulcer prevention were based for the most part on the same search strings used by Gorecki et al.30 An update of the searches was not planned because it can be assumed that outcome saturation is reached using our comprehensive search strategy.

Eligibility criteria

The COMET Handbook recommends that the scope of a review 'should be carefully considered in the context of the COS to ensure that outcomes are included from all relevant studies without unnecessary data collection'.¹¹ It emphasizes, as does the Cochrane Skin Core Outcome Set Initiative, that

not only clinical trials but also other study types like qualitative work should be considered.^{11,14} Therefore, even though our future COS should be applicable only for clinical trials on pressure ulcer prevention, other study types were also eligible for inclusion as they could contribute additional outcomes.

In this review, controlled trials and systematic reviews investigating the efficacy, effectiveness and/or safety of pressure ulcer prevention interventions, full health economic evaluations and any kind of primary studies and systematic reviews exploring PROs related to pressure ulcers or pressure ulcer prevention were eligible. If a publication such as a position paper appeared to the reviewer as relevant for the identification of pressure ulcer prevention outcomes, this criterion took precedence over the exclusion criteria regarding the study design and it was included as well. Due to the objective of this review the eligibility assessment process was therefore carried out in an inclusive rather than exclusive way.

For feasibility reasons, papers had to be published in the English language. No restrictions were set in terms of healthcare settings or publication date, except for the primary studies on PROs, which were only taken into account when they were published after 2008, as a systematic review by Gorecki et al. in 2009 on PROs related to pressure ulcer and other chronic wounds already existed.³⁰ Studies with a target population aged < 18 years and that included healthy volunteers only were excluded. A detailed list of the inclusion and exclusion criteria is shown in Appendix S2 (see Supporting Information).

Study selection

All identified publications were imported to the Covidence platform (www.covidence.org), which was used for the study selection procedures. After removal of duplicates, the references were assessed for eligibility based on title and abstract screening, followed by full-text screening. The evaluation was performed independently by pairs of two reviewers of the project team. Discrepancies were discussed within the project team in order to reach a final decision.

Data charting and synthesis

Data on key study characteristics (author, year, country, study type, type of intervention, healthcare setting and target population) and both outcomes and concepts that present potential outcomes for clinical trials were extracted into standardized data files by means of SPSS 23 (IBM, Armonk, NY, USA). The data extraction was performed by two reviewers independently and cross-checked by a third reviewer. Cases of disagreement were resolved among the data extractors through discussion. The concepts of outcomes were extracted as presented in the studies. Based on an inductive approach, the identified potential outcomes of the literature were compiled to overarching outcome domains by two project members in cooperation and were reviewed by the whole project team. Identified outcome domains were then assigned to broader

published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists

outcome domains and core areas according to the taxonomy of Dodd et al. $^{31}\,$

This newly developed taxonomy of Dodd *et al.* comprises 38 overall domains, allocated to the five core areas 'death', 'physiological/clinical', 'life impact', 'resource use' and 'adverse events'. Tools measuring health-related quality of life, which comprised several questions and therefore covered multiple outcome domains, were classified within each of the separate domains, as recommended by COMET and Dodd *et al.*^{31,32} Outcomes were only allocated to 'global quality of life' when patients were generally asked to assess their quality of life. Specifically reported adverse events were classified within the most suitable outcome domain and marked as 'adverse event'.^{31,32}

Results

Study selection

The searches identified 4498 references. After removal of duplicates and title and abstract screening, 668 full-text publications were evaluated for eligibility. Finally, 357 publications were included for data extraction (Figure 2).

Included publications

The included publications comprised 51 reviews and 281 primary studies. Twenty-five publications were identified as additional articles on a study already included. Most of the included studies were randomized controlled trials or controlled trials (n = 190). The other primary studies were identified as qualitative studies (n = 24) or full health economic evaluations (n = 21) or were allocated to the category 'other' (n = 46). The category 'other' comprised among others pre- and postimplementation studies, a series of single-case studies, a quasiexperimental study with interrupted time-series design and case-control studies. These studies were included as the reviewers assessed these publications as beneficial in the identification of pressure ulcer prevention outcomes, which took precedence over the study design.

Identified outcomes

Based on all identified outcomes in the included studies, 68 outcome domains were inductively created (Table 1). A detailed description of the extracted terms per outcome is shown in Appendix S3 (see Supporting Information). Most of the identified outcomes belonged to the outcome domain 'skin and subcutaneous tissue outcomes' according to Dodd et al.³¹ To this broad outcome domain of Dodd et al. we have allocated 21 outcome domains such as 'tissue oxygenation', 'skin temperature' or 'pressure ulcer occurrence'. Pressure ulcer occurrence referring to the whole body (no. 18) was reported in 168 studies (95 clinical trials, 36 other primary studies and 37 reviews) and pressure ulcer occurrence referring to distinct body sites (no. 19) in 64 studies (51 clinical trials, seven other primary studies and six reviews). Therefore, pressure ulcer occurrence was the most frequently captured outcome overall. There was a great variety in the terminology and reporting of pressure ulcer (Appendix S3, no.18).

When reporting the frequency of pressure ulcer occurrence the included references stated among other measures the



Figure 2 Flowchart of the screening and eligibility assessment process. CT, controlled trial; PRO, patient-reported outcome; PU, pressure ulcer; RCT, randomized controlled trial.

No.Conconsiderant (from influence approach)dird ratioInterviewConconstantConconstant1Exch (reg)1111MontalConconstantConconstant3Septers21111MontalMontal4Septers2212ConconstantData3Septers21111MontalData4Septers21111MontalData5Septers11111MontalData6Septers11111MontalData8Septers11111MontalData8Septers11111MontalData9Septers11111MontalData9Septers11111MontalData9Septers11111MontalData9Septers11111MontalData9Septers11111MontalData9Septers11111MontalData9Septers1111MontalDataData9Septers111 <t< th=""><th>No. 2 2 4</th><th></th><th></th><th>- / -</th><th></th><th></th><th></th></t<>	No. 2 2 4			- / -			
Inclusion Inclusion Inclusion Destination Destinon Destinon Desti	1 0 6 4	Outcome domain (from inductive approach)	clinical trials	primary studies	in reviews	Outcome domain (Core area
1 1 1 1 2 Canadi oncomes of a point of a balance Py canadi oncomes of a balance Py canadi oncomes of a balance Py canadi oncomes 8 Veght dange 1 1 1 2 Canadi oncomes 8 None 1 1 1 2 Canadi oncomes 9 None 1 1 1 2 Canadi oncomes 9 Sing ubalance 1 1 1 2 Canadi oncomes 11 None 1 1 1 2 Canadi oncomes 11 None 1 1 1 2 Canadi oncomes 11 None 1 1 1 2 Canadi oncomes 12 None 1 1 1 2 Canadi oncomes 13 None 1 1 1 2 Canadi oncomes 13 None 1 1 1 1 2 14 None	× 2 ∞ 4	Death reported as adverse event	1	/	/	1. Mortality/survival	Death
3 April: 2 2 3 April: 5 April: 2 1 2 4 4 6 Facural statement 1 1 2 6 <	ω4	Fatigue	/	1	2	9. General outcomes	Physiological/clinical
 Wight change Wight change Benné' Ablance Benné Ablance Bené Ablance	4	Appetite	/	2	/	9. General outcomes	
6Patter, halter,/1100Creend outcomes7Patter, holy preprint,111000008Patter, holy preprint,11100		Weight change	2	1	2	9. General outcomes	
7Form Balance9Consult backprotections8Ring fortance11199Sold protection111999Sold protection1119910Falls spends a solvere event1119911Diminis spends a solvere event1119912Diminis spends a solvere event1119913Nutritional and2999914Nutritional static21119915Nutritional static311199916Nutritional static3111199917Nutritional static31111111118Nutritional static3111	5	Patient's balance	/	1	~	9. General outcomes	
7 Function 9 General outcomes 3 String of denseres 1 1 9 General outcomes 3 Brig of deplacement 1 1 9 General outcomes 1 Indus sprorted as advecse event 1 1 9 General outcomes 1 Brids sprorted as advecse event 1 1 9 General outcomes 1 Broken event 2 1 1 Advector event 9 1 Broken event 2 1 1 4 Advector event 1 Broken event 2 1 1 4 Advector event 1 Advector event 2 1 1 4 Advector event 1 Advector event regetuing reprotion advector event 1 1 4 4 4 4 1 Advector event regetuing reprotion advector event regetuing reprotion events 1 4 4 4 4 1 Advector event regetuing reprotion advector rege	9	Posture	1	1	~	9. General outcomes	
8Bitty orbitation $/$	7	Patient's body perception	1	/	~	9. General outcomes	
9Boyl diplacement///19. General outcomes1Injurés reported as adverse event1129. General outcomes1Injurés reported as adverse event1119. General outcomes13Bood marker31111114Nutritonal status31111115Notentiation or confusion reported a adverse event1111116Nutritonal status311111117Alverse event3111111118Nutritonal status31111111119Pressure ulor contrustore111 <td>8</td> <td>Sitting tolerance</td> <td>/</td> <td>/</td> <td>2</td> <td>9. General outcomes</td> <td></td>	8	Sitting tolerance	/	/	2	9. General outcomes	
10Eight sproted an diverse event1129. Gerend outcoms11Injurise seported a adverse event119. Gerend outcoms12Biocitatation reported a adverse event119. Gerend outcoms13Bioti malic2119. Gerend outcoms14Nutritional status2119. Gerend outcoms15Nutritional status31119. Gerend outcoms16Adverse event regarding replatory tract31119. Gerend outcoms17Nutritional status311111118Nutritional status311111119Nutritional status3233311110Nutritional status111123311 <t< td=""><td>6</td><td>Body displacement</td><td>/</td><td>/</td><td>1</td><td>9. General outcomes</td><td></td></t<>	6	Body displacement	/	/	1	9. General outcomes	
11 Dignise and one of event. / 1 > Ceneral outcomes 12 Dispetianzion or confrision reported an dverse event. / 1 > General outcomes 13 Blood marker / 1 > General outcomes 14 Nutritional status / / > General outcomes 15 Nutritional status / / > 1 + Mecholism and turition outcomes 16 Averse events regarding react 1 1 > General outcomes 17 Pressue ulser courrence - whole objy 5 3 3 1 > 1	10	Falls reported as adverse event	1	1	2	9. General outcomes	
12 Bostienation er confusion reported as advecte creat / 1 9. Gareral outcomes 13 Bood anzles 2 / 1 14. Metabolism and antrition outcomes 14 Nurthonal stans 3 / 1 14. Metabolism and antrition outcomes 15 Nurthonal stans 3 / 1 14. Metabolism and antrition outcomes 16 Adverse event regarding repairatory tract 1 1 14. Metabolism and antrition outcomes 17 Adverse event regarding repairatory tract 1 1 14. Metabolism and antrition outcomes 18 Adverse event regarding repairatory tract 1 1 1 12. Repairatory tract 18 Adverse events regarding repairatory tract 1 1 1 1 12. Repairatory tracts 19 Pressue uler occurrence - défined body stats 3 3 35. Stan ad subcrutones state outcomes 21 Pressue uler occurrence - défined body stats 2 35. Stan ad subcrutones itsne outcomes 22 Tasseu uler occurrence - défined by stats 2 35. Stan ad subcrutones itsne outcomes 23 Biod perfixion 2 3<	11	Injuries reported as adverse event	/	1	/	9. General outcomes	
13Bold marker14Hondolism and muttion outcomes14Nurticional stans2711Hondolism and muttion outcomes15Nurticional stans3711Hondolism and muttion outcomes16Advense event regarding renal functioning7711Hondolism and untrition outcomes18Advense event regarding renal functioning7111Hondolism and untrition outcomes18Pressure ulero occurrence - define body9536372.8 km and subcurators tistero outcomes19Pressure ulero occurrence - define body322.8 km and subcurators tistero outcomes10Pressure ulero occurrence - define body322.8 km and subcurators tistero outcomes11Pressure ulero occurrence - define body30002.8 km and subcurators tistero outcomes12Pressure ulero occurrence - define body3112.8 km and subcurators tistero outcomes13Body perfixion3122.8 km and subcurators tistero outcomes14372.8 km and subcurators tistero outcomes15Tristero systemation3122.8 km and subcurators tistero outcomes15Tristero systemation3122.8 km and subcurators tistero outcomes16Tristero stans4322.8 km and subcurators tistero outcomes18Roticrators tistero122.8 km and subcurator	12	Disorientation or confusion reported as adverse event	/	1	/	9. General outcomes	
14Nutritional stants//11.4. Metabolism and nutrition outcomes15Nutritional indust3/111Metabolism and nutrition outcomes16Adverse events regarding reard functioning1119. Real and unitary outcomes17Adverse events regarding reard functioning1119. Real and unitary outcomes18Pressure ulere occurrence - which body9332. Repiratory, thoracic and mediastinal outcomes19Pressure ulere occurrence - derice related223. Ruad subcurators issue outcomes10Pressure ulere occurrence - derice related223. Ruad subcurators issue outcomes11Pressure ulere occurrence - derice related223. Ruad subcurators issue outcomes12Pressure ulere occurrence - derice related223. Ruad subcurators issue outcomes13Biold perfision31723. Rin and subcurators issue outcomes1431723. Rin and subcurators issue outcomes15Fraste under precursor sign/skin changes1123. Rin and subcurators issue outcomes16Pressure ulere precursor sign/skin changes123. Rin and subcurators issue outcomes17Taste unspectance3223. Rin and subcurators issue outcomes18Pressue ulere precursor sign/skin changes123. Rin and subcurators issue outcomes19Pressue ulere	13	Blood marker	2	/	1	14. Metabolism and nutrition outcomes	
15 Nutritional indic 3 / 1 1, Merabian and nutrition outcomes 17 Adverse event regarding reprinty tract 1 1 2 Regulation and nutrition outcomes 17 Adverse event regarding reprinty tract 1 1 2 Regulation and nutrition outcomes 18 Pressure uler occurrence – whole body, 53 3	14	Nutritional status	/	/	1	14. Metabolism and nutrition outcomes	
16 Àdrense event regarding renal functioning / / 1 1 9. Renal and urinary outcomes 17 Pessure uleer occurrence - valoie obdy 55 37 23. Shin and subcuratons its event ones 18 Pressure uleer occurrence - valoie obdy 51 7 23. Shin and subcuratons its event comes 20 Pressure uleer occurrence - defined body sites 2 3 3 3 3 21 Pressure uleer occurrence - defined body sites 2 3 3 3 3 3 3 21 Pressure uleer occurrence - defined body sites 2 3 3 1 3 3 1 3 3 4 3 3 4 3 3 1 3 3 1 3 3 1 3 3 1 3	15	Nutritional intake	3	/	1	14. Metabolism and nutrition outcomes	
17Adverse events regarding respiratory tract1112.1. Respiratory, thoract and mediastinal outcomes18Pressure ulere contractere – Wolde body9536373.5. Kin and subcharators tissue outcomes20Pressure ulere contractere – Wolde body21702.5. Kin and subcharators tissue outcomes21Pressure ulere contractere – Wolde body3173.5. Kin and subcharators tissue outcomes21Pressure ulere contractere – Wolde body30603.5. Kin and subcharators tissue outcomes22Pressure ulere status (deterioration, helling, wound status)30603.5. Kin and subcharators tissue outcomes23Rine and subcharators tissue outcomes2172.3. Skin and subcharators tissue outcomes24Tissue oxygenation3172.3. Skin and subcharators tissue outcomes25Tanscutaterous cribon dioxide1172.3. Skin and subcharators tissue outcomes26Pressue ulere precursor signs/skin changes133.5. Kin and subcharators tissue outcomes27Tanse oxygenation3112.3. Skin and subcharators tissue outcomes28Transe oxygenation312.3. Skin and subcharators tissue outcomes29Tanse oxygenation33.5. Kin and subcharators tissue outcomes29Skin temperature412.3. Skin and subcharators tissue outcomes29Skin temperature3Skin function <td>16</td> <td>Adverse event regarding renal functioning</td> <td>/</td> <td>/</td> <td>1</td> <td>19. Renal and urinary outcomes</td> <td></td>	16	Adverse event regarding renal functioning	/	/	1	19. Renal and urinary outcomes	
18 Pressure uler occurrence – whole body 95 36 37 23. Skin and subcutanous tissue outcomes 19 Pressure uler occurrence – defined body sites 51 7 6 23. Skin and subcutanous tissue outcomes 20 Pressure uler occurrence – defined body sites 21 7 6 23. Skin and subcutanous tissue outcomes 21 Pressure uler staus (deterioration, haling, wound stans) 30 6 23. Skin and subcutanous tissue outcomes 23 Biod perfusion 3 1 7 23. Skin and subcutanous tissue outcomes 24 Transcutaneous carbon dioxide / / 23 Skin and subcutanous tissue outcomes 25 Transcutaneous carbon dioxide / / 2 23. Skin and subcutanous tissue outcomes 26 Pressure uler precursor signs/ skin changes 1 2 3. Skin and subcutanous tissue outcomes 26 Pressure uler precursor signs/ skin changes 1 2 3. Skin and subcutanous tissue outcomes 26 Pressure uler precursor signs/ skin changes 1 2 3. Skin and subcutanous tissue outcomes 28 Skin trutuere 3 1 2 3	17	Adverse events regarding respiratory tract	1	1	/	22. Respiratory, thoracic and mediastinal outcomes	
19 Presure ulcer occurrence - defined body sites 51 7 6 23. Skin and subcutanous tissue outcomes 20 Presure ulcer occurrence - device related 2 1 23. Skin and subcutanous tissue outcomes 21 Presure ulcer occurrence - device related 2 3 6 0 23. Skin and subcutanous tissue outcomes 21 Interface presure 27 9 11 23. Skin and subcutanous tissue outcomes 23 Blood perfusion 8 0 9 23. Skin and subcutanous tissue outcomes 24 Tissue ovygeration 8 1 7 23. Skin and subcutanous tissue outcomes 24 Pressure ulcer pressor signs/skin changes 1 7 23. Skin and subcutanous tissue outcomes 25 Transcutaneous carbon dioxide 1 7 23. Skin and subcutanous tissue outcomes 26 Pressure ulcer pressor signs/skin changes 1 7 23. Skin and subcutanous tissue outcomes 26 Pressure ulcer 1 23. Skin and subcutanous tissue outcomes 23. Skin and subcutanous tissue outcomes 28 Rin temperature 1 23. Skin and subcutanous tissue outcomes <t< td=""><td>18</td><td>Pressure ulcer occurrence – whole body</td><td>95</td><td>36</td><td>37</td><td>23. Skin and subcutanous tissue outcomes</td><td></td></t<>	18	Pressure ulcer occurrence – whole body	95	36	37	23. Skin and subcutanous tissue outcomes	
20Pressure ulcer courcnece - device related21/23. Skin and subcutanous fisate outcomes21Inerface pressure2791123. Skin and subcutanous fisate outcomes23Blood persion2791123. Skin and subcutanous fisate outcomes24Tisue oxygenation31723. Skin and subcutanous fisate outcomes25Transcutaneous carbon dioxide7723. Skin and subcutanous fisate outcomes26Tisue oxygenation31723. Skin and subcutanous fisate outcomes27Pressure ublity723. Skin and subcutanous fisate outcomes28Kin temperature1223. Skin and subcutanous fisate outcomes29Body core temperature123. Skin and subcutanous fisate outcomes30Skin structure323. Skin and subcutanous fisate outcomes31Itsue total123. Skin and subcutanous fisate outcomes32Skin structure323. Skin and subcutanous fisate outcomes33Muscle tomas1223. Skin and subcutanous fisate outcomes34Tissue deformation1223. Skin and subcutanous fisate outcomes35Pain associated with pressure uler1223. Skin and subcutanous fisate outcomes36Skin structure323. Skin and subcutanous fisate outcomes37Muscle tomas1223. Skin and subcutanous fisate outcomes38Muscle tomas1223.	19	Pressure ulcer occurrence – defined body sites	51	7	6	23. Skin and subcutanous tissue outcomes	
21Presure ulcer status (deterioration, healing, wound status)30623 Skin and subcutanous tistue outcomes22interfee presure2791123 Skin and subcutanous tistue outcomes24Tusue oxygenation31723 Skin and subcutanous tistue outcomes25Tusue oxygenation31723 Skin and subcutanous tistue outcomes26Pressure ulcer precursor signs/skin changes1223 Skin and subcutanous tistue outcomes27Transcutaneous carbon dioxide12223 Skin and subcutanous tistue outcomes28Fressure ulcer precursor signs/skin changes143323 Skin and subcutanous tistue outcomes28Kin superature41223 Skin and subcutanous tistue outcomes29Body core temperature1123 Skin and subcutanous tistue outcomes29Body core temperature1123 Skin and subcutanous tistue outcomes30Skin structure3223 Skin and subcutanous tistue outcomes31Skin thincion41223 Skin and subcutanous tistue outcomes33Musc foncine1123 Skin and subcutanous tistue outcomes34Tistue deformation1123 Skin and subcutanous tistue outcomes35Pain associated with intervention1223 Skin and subcutanous tistue outcomes36Pain associated with intervention1223 Skin and subcutanous tistue outcomes3	20	Pressure ulcer occurrence – device related	2	1	/	23. Skin and subcutanous tissue outcomes	
21Interface pressure2791123. Skin and subcutanous tissue outcomes23Blod perfusion80923. Skin and subcutanous tissue outcomes24Tissue oxygenation31723. Skin and subcutanous tissue outcomes25Transcutaneous carbon dioxide//223. Skin and subcutanous tissue outcomes26Pressue uker precursor signs/skin changes14323. Skin and subcutanous tissue outcomes27Tissue viability//123. Skin and subcutanous tissue outcomes28Skin temperature+//123. Skin and subcutanous tissue outcomes29Body core temperature+//123. Skin and subcutanous tissue outcomes20Skin temperature+//123. Skin and subcutanous tissue outcomes21Skin function+//123. Skin and subcutanous tissue outcomes23Muscle thickness1/223. Skin and subcutanous tissue outcomes34Tissue selformation+//223. Skin and subcutanous tissue outcomes35Muscle thickness1//223. Skin and subcutanous tissue outcomes36Muscle thickness1//223. Skin and subcutanous tissue outcomes37Muscle thickness1//223. Skin and subcutanous tissue outcomes38Muscle tonus/1 <td< td=""><td>21</td><td>Pressure ulcer status (deterioration, healing, wound status)</td><td>30</td><td>6</td><td>6</td><td>23. Skin and subcutanous tissue outcomes</td><td></td></td<>	21	Pressure ulcer status (deterioration, healing, wound status)	30	6	6	23. Skin and subcutanous tissue outcomes	
23Blood perfusion80923. Skin and subcutanous fisue outcomes24Transcuaneous carbon dioxide31723. Skin and subcutanous tisue outcomes25Transcuaneous carbon dioxide///23. Skin and subcutanous tisue outcomes26Pressure uler precursor signs/skin changes143323. Skin and subcutanous tisue outcomes27Tisue withility//123. Skin and subcutanous tisue outcomes28Fin tamperature4//12.3. Skin and subcutanous tisue outcomes29Body core temperature1//2.3. Skin and subcutanous tisue outcomes30Skin structure3/12.3. Skin and subcutanous tisue outcomes31Skin function4//2.3. Skin and subcutanous tisue outcomes33Muscle thickness1/2.3. Skin and subcutanous tisue outcomes34Tisus edormation4//2.3. Skin and subcutanous tisue outcomes35Pressure uler1/2.3. Skin and subcutanous tisue outcomes36Muscle tomis1/2.3. Skin and subcutanous tisue outcomes37Muscle tomis1/2.3. Skin and subcutanous tisue outcomes38Ansel thickness1/12.3. Skin and subcutanous tisue outcomes39Pressociated with pressure uler1/2.3. Skin and subcutanous tisue outcomes36Pain associated with	22	Interface pressure	27	6	11	23. Skin and subcutanous tissue outcomes	
24Tissue oxygenation31723. Skin and subcutanous tissue outcomes25Transcutaneous carbon dioxide///23. Skin and subcutanous tissue outcomes26Pressue ufer precursor signs/skin changes1332. Skin and subcutanous tissue outcomes27Tissue viability//12. Skin and subcutanous tissue outcomes28Skin temperature4//12. Skin and subcutanous tissue outcomes29Body core temperature1//12. Skin and subcutanous tissue outcomes30Skin structure3/12. Skin and subcutanous tissue outcomes31Skin function4/22. Skin and subcutanous tissue outcomes32Muscle thickness1/12. Skin and subcutanous tissue outcomes33Muscle toinus1/22. Skin and subcutanous tissue outcomes34Tissue deformation1/12. Skin and subcutanous tissue outcomes35Pain associated with intervention1/2. Skin and subcutanous tissue outcomes36Pain associated with intervention112. Skin and subcutanous tissue outcomes37Pressure ulcer102432. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue outcomes12. Skin and subcutanous tissue outcomes37Pressure relief performance111 <td< td=""><td>23</td><td>Blood perfusion</td><td>8</td><td>0</td><td>6</td><td>23. Skin and subcutanous tissue outcomes</td><td></td></td<>	23	Blood perfusion	8	0	6	23. Skin and subcutanous tissue outcomes	
25 Transcutaneous carbon dioxide / / 2 2.3. Skin and subcutanous tissue outcomes 26 Pressure ulcer precursor signs/skin changes 14 3 3 2.3. Skin and subcutanous tissue outcomes 27 Tissue viability / / 1 2.3. Skin and subcutanous tissue outcomes 28 Skin temperature 4 / 1 2.3. Skin and subcutanous tissue outcomes 29 Body core temperature 1 / / 2.3. Skin and subcutanous tissue outcomes 30 Skin structure 3 / 1 2.3. Skin and subcutanous tissue outcomes 31 Skin structure 3 / 1 2.3. Skin and subcutanous tissue outcomes 32 Muscle thickness 1 / 1 2.3. Skin and subcutanous tissue outcomes 33 Muscle thickness 1 / 2.3. Skin and subcutanous tissue outcomes 34 Tissue deformation 1 / 2.3. Skin and subcutanous tissue outcomes 35 Pain associated with pressure ulcer 1 2.3. Skin and subcutanous tissue outcomes 35 Pain associated with pressure ulcer 1 <td>24</td> <td>Tissue oxygenation</td> <td>3</td> <td>1</td> <td>7</td> <td>23. Skin and subcutanous tissue outcomes</td> <td></td>	24	Tissue oxygenation	3	1	7	23. Skin and subcutanous tissue outcomes	
26Pressure ulcer precursor signs/skin changes143323. Skin and subcutanous tissue outcomes27Tissue viability///123. Skin and subcutanous tissue outcomes28Skin temperature4//123. Skin and subcutanous tissue outcomes29Body core temperature1//123. Skin and subcutanous tissue outcomes30Skin structure3//123. Skin and subcutanous tissue outcomes31Skin function3/123. Skin and subcutanous tissue outcomes32Muscle tionus3/123. Skin and subcutanous tissue outcomes33Muscle tonus/1/23. Skin and subcutanous tissue outcomes34Tissue deformation1/123. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1123. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue outcomes//123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue/1123. Skin and subcutanous tissue outcomes37Pressure relief performance//1123. Skin and subcutanous t	25	Transcutaneous carbon dioxide	/	/	2	23. Skin and subcutanous tissue outcomes	
27Tissue viability//123. Skin and subcutanous tissue outcomes28Skin temperature4/623. Skin and subcutanous tissue outcomes29Body core temperature1//23. Skin and subcutanous tissue outcomes30Skin structure3/123. Skin and subcutanous tissue outcomes31Skin function4/223. Skin and subcutanous tissue outcomes32Muscle thickness1/223. Skin and subcutanous tissue outcomes33Muscle tonus1/223. Skin and subcutanous tissue outcomes34Tissue deformation1/223. Skin and subcutanous tissue outcomes35Pain associated with intervention123. Skin and subcutanous tissue outcomes36Pain associated with intervention123. Skin and subcutanous tissue outcomes37Pressure relief performance/123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue outcomes23. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue7/139Yeis and subcutanous tissue outcomes23. Skin and subcutanous tissue outcomes	26	Pressure ulcer precursor signs/skin changes	14	3	3	23. Skin and subcutanous tissue outcomes	
28Skin temperature4/623. Skin and subcutanous tissue outcomes29Body core temperature1//23. Skin and subcutanous tissue outcomes30Skin structure3/123. Skin and subcutanous tissue outcomes31Skin function4/223. Skin and subcutanous tissue outcomes32Muscle thickness1/223. Skin and subcutanous tissue outcomes33Muscle thickness1/223. Skin and subcutanous tissue outcomes34Tissue deformation1/223. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue7/323. Skin and subcutanous tissue outcomes	27	Tissue viability	/	/	1	23. Skin and subcutanous tissue outcomes	
29Body core temperature1/23. Skin and subcutanous tissue outcomes30Skin structure3/123. Skin and subcutanous tissue outcomes31Skin function4/223. Skin and subcutanous tissue outcomes32Muscle thickness1/223. Skin and subcutanous tissue outcomes33Muscle tonus1/1223. Skin and subcutanous tissue outcomes34Tissue deformation/1/223. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue outcomes323. Skin and subcutanous tissue outcomes	28	Skin temperature	4	/	6	23. Skin and subcutanous tissue outcomes	
30Skin structure3/123. Skin and subcutanous tissue outcomes31Skin function4/223. Skin and subcutanous tissue outcomes32Muscle thickness1/223. Skin and subcutanous tissue outcomes33Muscle tonus1/1/234Tissue deformation/1/223. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue outcomes/123. Skin and subcutanous tissue outcomes	29	Body core temperature	1	/	~	23. Skin and subcutanous tissue outcomes	
31Skin function4/223. Skin and subcutanous tissue outcomes32Muscle thickness1/223. Skin and subcutanous tissue outcomes33Muscle tonus/1/223. Skin and subcutanous tissue outcomes34Tissue deformation/1/223. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutanous tissue outcomes/123. Skin and subcutanous tissue outcomes	30	Skin structure	3	/	1	23. Skin and subcutanous tissue outcomes	
32Muscle thickness1/223. Skin and subcutanous tissue outcomes33Muscle toruus/1/23. Skin and subcutanous tissue outcomes34Tissue deformation/1/23. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutaneous tissue7/323. Skin and subcutanous tissue outcomes	31	Skin function	4	/	2	23. Skin and subcutanous tissue outcomes	
33Muscle torus/1/23. Skin and subcutanous tissue outcomes34Tissue deformation//123. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutaneous tissue7/323. Skin and subcutanous tissue outcomes	32	Muscle thickness	1	/	2	23. Skin and subcutanous tissue outcomes	
34Tissue deformation//123. Skin and subcutanous tissue outcomes35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutaneous tissue7/323. Skin and subcutanous tissue outcomes	33	Muscle tonus	/	1	~	23. Skin and subcutanous tissue outcomes	
35Pain associated with pressure ulcer1024323. Skin and subcutanous tissue outcomes36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutaneous tissue7/323. Skin and subcutanous tissue outcomes	34	Tissue deformation	/	/	1	23. Skin and subcutanous tissue outcomes	
36Pain associated with intervention16823. Skin and subcutanous tissue outcomes37Pressure relief performance/1123. Skin and subcutanous tissue outcomes38Adverse events regarding skin and subcutaneous tissue7/323. Skin and subcutanous tissue outcomes	35	Pain associated with pressure ulcer	10	24	3	23. Skin and subcutanous tissue outcomes	
37 Pressure relief performance / 1 1 23. Skin and subcutanous tissue outcomes 38 Adverse events regarding skin and subcutaneous tissue 7 / 3 23. Skin and subcutanous tissue outcomes	36	Pain associated with intervention	1	6	8	23. Skin and subcutanous tissue outcomes	
38 Adverse events regarding skin and subcutaneous tissue 7 / 3 23. Skin and subcutanous tissue outcomes	37	Pressure relief performance	/	1	1	23. Skin and subcutanous tissue outcomes	
	38	Adverse events regarding skin and subcutaneous tissue	7	/	3	23. Skin and subcutanous tissue outcomes	

Table 1 Outcome domain long list based on the review

		Frequency in	Frequency in other	Frequency	Taxonomy according to Dodd et al. ³¹	
No.	Outcome domain (from inductive approach)	clinical trials	primary studies	in reviews	Outcome domain	Core area
39	Autonomy and independence	1	4	1	25. Physical functioning	Life impact
40	Ability to move	11	16	1	25. Physical functioning	
41	Activities of daily living	ç	12	2	25. Physical functioning	
42	Ability to be active	/	5	1	25. Physical functioning	
43	Physical functioning	œ	6	1	25. Physical functioning	
44	Pressure ulcer prevention self-care	ç	6	3	25. Physical functioning	
45	Handling skills	_	/	1	25. Physical functioning	
46	Sleep	ç	7	/	25. Physical functioning	
47	Energy and vitality	4	5	/	25. Physical functioning	
48	Social functioning	4	14	2	26. Social functioning	
49	Role functioning	_	2	1	27. Role functioning	
50	Self-efficacy	1	9	_	28. Emotional functioning/wellbeing	
51	Willingness to change self-care	_	3	1	28. Emotional functioning/wellbeing	
52	Self-consciousness and self-esteem	/	6	/	28. Emotional functioning/wellbeing	
53	Emotional wellbeing	6	20	3	28. Emotional functional/wellbeing	
54	Privacy	\	1	_	28. Emotional functioning/wellbeing	
55	Knowledge of patient	∞	5	5	29. Cognitive functioning	
56	Global quality of life	1	2	13	30. Global quality of life	
57	General health/malaise	3	8	_	31. Perceived health status	
58	Patient satisfaction with intervention	5	3	5	32. Delivery of care	
59	Acceptability of intervention and comfort	31	10	18	32. Delivery of care	
60	Adherence and compliance	8	2	1	32. Delivery of care	
61	Access to service	1	3	_	32. Delivery of care	
62	Patient participation in care	1	1	/	32. Delivery of care	
63	Resource use (nonhospital)	4	3	1	34. Economic	Resource use
64	Costs	28	27	18	34. Economic	
65	Hospital resource use	4	7	5	35. Hospital	
66	Time investment by patient	_	1	_	37. Societal/carer burden	
67	Healthcare utilization	2		2	37. Societal/carer burden	
68	Any adverse events/safety	15	5	12	38. Adverse events/effects	Adverse events

Table 1 (continued)

incidence or the prevalence of pressure ulcers, hospital-acquired pressure ulcer prevalence, the raw numbers of pressure ulcers that occurred, or the time until occurrence. There were also differences in the reported categories (e.g. including or excluding category 1, only category 3 and above). Some publications assessed the whole body, whereas others defined specific body areas for the assessment of pressure ulcer occurrence. Examples of the verbatim text describing the body areas that were considered for evaluation are 'sacrum, hips and heels', 'sacrum, buttocks and heels', 'trunk and heels' and 'trochanter' (Appendix S3, no. 19).

The second most commonly reported outcome domain was 'costs', including cost outcomes that were associated with a prevention intervention in any manner, like cost savings per year, hospital costs or direct staff costs (Appendix S3, no. 64). Cost outcomes were reported in 73 studies. 'Acceptability of intervention and comfort' was another frequent outcome domain (reported in 59 studies, no. 59). This domain represents outcomes that were reported by patients.³³ Other examples of listed PROs are 'pain associated with pressure ulcer' (no. 35), 'pain associated with intervention' (no. 36), 'emotional wellbeing' (no. 53), 'patient satisfaction with intervention' (no. 58) and 'global quality of life' (no. 56).

In order to evaluate the success of a pressure ulcer prevention intervention, trials also assessed outcomes that were considered to correlate with the development of pressure ulcer occurrence, like 'interface pressure' (no. 22), 'blood perfusion' (no. 23), 'skin function' (no. 31) or 'tissue oxygenation' (no. 24). Domains like 'nutritional intake' (no. 15) and 'nutritional status' (no. 14) are examples of interventionspecific domains, which are relevant only for trials investigating nutritional supplementation.

Types of preventive interventions

Table 2 shows the most frequent types of preventive interventions used in the included studies. The effects of support surfaces for the bed were reported most frequently (n = 93), followed by trials that evaluated the implementation of any kind of preventive guidelines or programmes, like the implementation of educational programmes or bundle-of-care interventions (n = 47). Other interventions that were also common (reported in more than 20 studies) are the application of preventive dressings and repositioning.

Discussion

As described in previous systematic reviews,^{4,25,26} the reporting of pressure ulcer occurrence was heterogeneous. There were differences not only in how the occurrence of pressure ulcers was reported, but also regarding the body sites. Even when similar body areas were evaluated for the effectiveness of pressure ulcer prevention, a great variation of definitions exists (e.g. sacrum, buttocks, trochanter, trunk, pelvis). The use of the same terminology, classification systems and method to calculate pressure ulcer occurrence is important to enhance the comparison of study results.³⁴ The harmonization of capturing and reporting the identified core outcome domains will be a major task in future project steps, when it comes to developing the measurement methods.

Besides the occurrence of pressure ulcers, many other outcomes showed huge variation as well. For example, the indirect measure 'interface pressure' included, among others, the outcomes 'maximum interface pressure', 'mean interface pressure' and 'the average of highest four pressures'. Regarding 'blood perfusion' some studies measured the 'skin perfusion' and others the 'capillary blood flow' or 'tissue blood flow'. These examples emphasize again the difficulties that can emerge when trying to pool study results.

Our review results also indicate that there is heterogeneity between outcomes regarded as important in reviews and in primary studies. For example, 'sleep' was reported in primary studies, but not in any of the included reviews. On the other hand, some outcomes reported in the reviews were not applied in primary studies. This situation is similar in other fields. For example, a recently published review showed that 68% of dermatological trial outcomes were not included as outcomes in the corresponding Cochrane Reviews, and vice versa, 28% of outcomes defined by the reviewers were not reported in any supporting trial.³⁵ Similar observations have

Table 2	Types	of	preventive	interv	entions	reported	in	the	included	studies
---------	-------	----	------------	--------	---------	----------	----	-----	----------	---------

Type of preventive intervention	Reported in clinical trials (n)	Reported in other primary studies (n)	Reported in reviews (n)
Support surface – bed	66	20	7
Guideline, education, programmes	23	14	10
Dressings	23	2	3
Repositioning	13	4	4
Support surface – sitting position	14	3	2
Nutrition	6	4	3
Heel offloading	6	1	3
Any intervention or pressure ulcer prevention in general	0	2	4
Mobility promotion	0	1	0
Other	39	40	15

© 2020 The Authors. British Journal of Dermatology

published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists

been made in the fields of oncology³⁶ and preterm birth prevention.³⁷ This indicates that trialists and systematic reviewers differ in their opinions regarding relevant outcomes, which has the potential to result in research waste.³⁸ Therefore both trialists and systematic reviewers should participate as key stakeholders in the subsequent COS consensus process.

Some of the extracted outcomes seem more appropriate for trials of treatment rather than prevention interventions. For example, the outcomes 'pain associated with pressure ulcer' and 'pressure ulcer status' may appear unsuitable regarding pressure ulcer prevention, as they commonly appear in connection with ulcer treatment. However, these outcomes also fit into the concept of tertiary prevention, which describes the prevention of deterioration. This is why these outcomes were also extracted when reported in pressure ulcer prevention studies. The possible overlap between prevention and treatment outcomes was observed in other COS initiatives as well.³⁹⁻⁴¹ Therefore, one of the next steps is to further define the concept and levels of pressure ulcer prevention to be used in OUTPUTs. Furthermore, many intervention-specific outcomes were identified, such as 'weight gain' or 'nutritional status'. It must be decided whether it is more useful to develop an intervention-specific COS or a generic COS that is applicable for all types of interventions. In the latter case, intervention-specific outcomes are to be excluded.

This review included not only clinical trials and reviews, but also other study designs. The inclusion of qualitative studies is considered especially important, because they are a relevant source in identifying potential outcomes important for patients.⁴² Including other evidence sources in addition to published clinical trials increases the review and data extraction workload, but in this review it allowed us to identify the following eight outcome domains that would otherwise have been missed: 'appetite', 'patient's balance', 'injuries reported as adverse event', 'disorientation/confusion reported as adverse event', 'muscle tonus', 'self-consciousness and self-esteem', 'privacy' and 'time investment by patient'. Finding an optimal balance between more sensitive or more specific literature searches for long-list creation in COS development is challenging, but we support the statement that looking at published clinical trials only is insufficient.^{14,42}

The results of this review provide the basis for the next steps of the OUTPUTs initiative, whose main objective is to reduce this long list down to a consensus agreed list of essential outcome domains. Although the project group follows the latest methodological guidance, there are a number of methodological challenges in this new field, such as how best to involve patients in the development of a COS without overstraining them. Involving patients as participants in an e-Delphi survey might be difficult due to the complex question, which needs a deeper understanding of the concept of a COS. To ensure meaningful involvement of patients, it is essential to provide assistance and guidance. In addition, it is crucial that all outcome domains are presented with clear definitions, so that all participants understand their meaning and are able to rate their importance. Further, it is also not yet settled how to address the issue of timing.^{14,43} Variations in time periods over which studies are conducted are challenging regarding the interpretation of trial results.³⁴ Timing is therefore also a factor that might be considered in sorting out the heterogeneity of trial results. Whatever form this may take, it will probably be necessary to distinguish between timing in terms of indirect outcomes of pressure (e.g. blood perfusion, tissue oxygenation, interface pressure) and direct outcomes of prevention (pressure ulcer development regarding the whole body, regarding defined body sites or being device related).

Limitations of the study are as follows. Only papers in the English language were included in this review, which may be regarded as language bias. Although the literature search was conducted in the most relevant electronic databases, there might be publications that were not identified. Qualitative studies were included to capture the views of patients and service users. Nevertheless, additional ways are needed to identify possibly missing outcomes, such as direct interviews with patients. The review was completed in 2016. Because data saturation was reached, it is unlikely that new outcomes have been introduced in the literature since then.

In conclusion, pressure ulcer occurrence is the most commonly reported outcome in pressure ulcer prevention research, but there is also a wide range of other outcomes. So far, there has not been a harmonization regarding the relevance of the single outcomes. OUTPUTs will help to prioritize and standardize the outcome selection in future pressure ulcer prevention trials.

Author Contribution

Anna Lechner: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Project administration (equal); Visualization (equal); Writing-original draft (lead); Writing-review & editing (lead). Jan Kottner: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Project administration (equal); Supervision (equal); Writing-review & editing (supporting). Susanne Coleman: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Project administration (equal); Supervision (equal); Writing-review & editing (supporting). Delia Muir: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Project administration (equal); Supervision (equal). Dimitri Beeckman: Conceptualization (equal); Methodology (equal); Supervision (equal); Writing-review & editing (supporting). Wendy Chaboyer: Conceptualization (equal); Methodology (equal); Supervision (equal); Writing-review & editing (supporting). Janet Cuddigan: Conceptualization (equal); Methodology (equal); Supervision (equal); Writingreview & editing (supporting). Zena E. H. Moore: Conceptualization (equal); Methodology (equal); Supervision (equal); Writing-review & editing (supporting). Claudia Rutherford: Conceptualization (equal); Methodology (equal); Supervision (equal); Writing-review & editing (supporting). Jochen Sch**mitt:** Conceptualization (equal); Methodology (equal); Supervision (equal); Writing-review & editing (supporting). Jane Nixon: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Project administration (equal); Supervision (equal); Writing-review & editing (supporting). Katrin Balzer: Conceptualization (equal); Data curation (equal); Investigation (equal); Methodology (equal); Project administration (equal); Supervision (equal); Writingreview & editing (supporting).

References

- National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Quick Reference Guide (Haesler E, ed.). Osborne Park, Australia: Cambridge Media, 2014.
- 2 Coleman S, Nixon J, Keen J et al. A new pressure ulcer conceptual framework. J Adv Nurs 2014; **70**:2222–34.
- 3 Haesler E, Kottner J, Cuddigan J. The 2014 International Pressure Ulcer Guideline: methods and development. J Adv Nurs 2017; **73**:1515–30.
- 4 Tomova-Simitchieva T, Akdeniz M, Blume-Peytavi U et al. [The epidemiology of pressure ulcer in Germany: systematic review]. Gesundheitswesen 2019; **81**:505–12 (in German).
- 5 VanGilder C, Lachenbruch C, Algrim-Boyle C, Meyer S. The International Pressure Ulcer Prevalence Survey: 2006–2015: a 10-year pressure injury prevalence and demographic trend analysis by care setting. J Wound Ostomy Continence Nurs 2017; 44:20–8.
- 6 Tubaishat A, Papanikolaou P, Anthony D, Habiballah L. Pressure ulcers prevalence in the acute care setting: a systematic review, 2000–2015. Clin Nurs Res 2017; 27:643–59.
- 7 Smith PG, Morrow RH, Ross DA. Outcome measures and case definition. In: Field Trials of Health Interventions: a Toolbox (Smith PG, Morrow RH, Ross DA, eds), 3rd edn. Oxford: Oxford University Press, 2015; Chapter 13.
- 8 Chalmers I, Bracken MB, Djulbegovic B et al. How to increase value and reduce waste when research priorities are set. Lancet 2014; 383:156–65.
- 9 Evans I, Thornton H, Chalmers I, Glasziou P, eds. Testing Treatments: Better Research for Better Healthcare. London: Pinter & Martin, 2011.
- 10 Haidich AB. Meta-analysis in medical research. Hippokratia 2010; 14 (Suppl. 1):29–37.
- 11 Williamson PR, Altman DG, Bagley H et al. The COMET Handbook: version 1.0. Trials 2017; 18 (Suppl. 3):280.
- 12 Kirkham JJ, Davis K, Altman DG et al. Core Outcome Set-STAndards for Development: the COS-STAD recommendations. PLOS Med 2017; 14:e1002447.
- 13 Schmitt J, Deckert S, Alam M et al. Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). Br J Dermatol 2016; 174:287–95.
- 14 Kottner J, Jacobi L, Hahnel E et al. Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. Br J Dermatol 2018; 178:e279–85.
- 15 Schmitt J, Apfelbacher C, Spuls PI et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol 2015; 135:24–30.
- 16 Prinsen CAC, Vohra S, Rose MR et al. How to select outcome measurement instruments for outcomes included in a 'Core Outcome Set' – a practical guideline. Trials 2016; 17:449.
- 17 Lechner A, Kottner J, Coleman S et al. Outcomes for Pressure Ulcer Trials (OUTPUTs): protocol for the development of a

core domain set for trials evaluating the clinical efficacy or effectiveness of pressure ulcer prevention interventions. Trials 2019; **20**:449.

- 18 Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implement Sci 2010; 5:69.
- 19 Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005; 8:19–32.
- 20 Peterson J, Pearce PF, Ferguson LA, Langford CA. Understanding scoping reviews: definition, purpose, and process. J Am Assoc Nurse Pract 2017; 29:12–16.
- 21 Colquhoun HL, Levac D, O'Brien KK et al. Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol 2014; 67:1291–4.
- 22 Chou R, Dana T, Bougatsos C et al. Pressure ulcer risk assessment and prevention: a systematic comparative effectiveness review. *Ann* Intern Med 2013; **159**:28–38.
- 23 Langer G, Fink A. Nutritional interventions for preventing and treating pressure ulcers. Cochrane Database Syst Rev 2014; 2014: CD003216.
- 24 McInnes E, Jammali-Blasi A, Bell-Syer S et al. Preventing pressure ulcers – are pressure-redistributing support surfaces effective? A Cochrane systematic review and meta-analysis. Int J Nurs Stud 2012; 49:345–59.
- 25 McInnes E, Jammali-Blasi A, Bell-Syer SE et al. Support surfaces for pressure ulcer prevention. Cochrane Database Syst Rev 2015; 2015: CD001735.
- 26 Moore ZE, Webster J. Dressings and topical agents for preventing pressure ulcers. Cochrane Database Syst Rev 2013; 2013:CD009362.
- 27 Moore ZE, Cowman S. Risk assessment tools for the prevention of pressure ulcers. Cochrane Database Syst Rev 2014; 2014: CD006471.
- 28 Moore ZE, Webster J, Samuriwo R. Wound-care teams for preventing and treating pressure ulcers. Cochrane Database Syst Rev 2015; 2015:CD011011.
- 29 Porter-Armstrong AP, Moore ZE, Bradbury I, McDonough S. Education of healthcare professionals for preventing pressure ulcers. Cochrane Database Syst Rev 2018; 5:CD011620.
- 30 Gorecki C, Brown JM, Nelson EA et al. Impact of pressure ulcers on quality of life in older patients: a systematic review. J Am Geriatr Soc 2009; 57:1175–83.
- 31 Dodd S, Clarke M, Becker L et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol 2018; 96:84–92.
- 32 COMET Initiative. Outcome classification. Available at: http:// www.comet-initiative.org/Resources/OutcomeClassification (last accessed 17 July 2020).
- 33 Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res 2011; 2:137-44.
- 34 National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and treatment of pressure ulcers/injuries: clinical practice guideline. Available at: http://www.internationalguideline.com (last accessed 17 July 2020).
- 35 Schmitt J, Lange T, Kottner J et al. Cochrane reviews and dermatological trials outcome concordance: why core outcome sets could make trial results more usable. J Invest Dermatol 2019; 139:1045–53.
- 36 Hirsch BR, Califf RM, Cheng SK et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials. gov. JAMA Intern Med 2013; 173:972–9.
- 37 Meher S, Alfirevic Z. Choice of primary outcomes in randomised trials and systematic reviews evaluating interventions for preterm birth prevention: a systematic review. BJOG 2014; 121:1188–94.

- 38 Glasziou P, Altman DG, Bossuyt P et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014; 383:267–76.
- 39 Rönsch H, Apfelbacher C, Brans R et al. Which outcomes have been measured in hand eczema trials? A systematic review. Contact Dermatitis 2019; 80:201–7.
- 40 Lamont TJ, Clarkson JE, Ricketts DNJ et al. Core outcomes in periodontal trials: study protocol for core outcome set development. Trials 2017; 18:436.
- 41 Meher S, Cuthbert A, Kirkham JJ et al. Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG 2019; 126:83–93.
- 42 Gorst SL, Young B, Williamson PR et al. Incorporating patients' perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. BMJ Open Diabetes Res Care 2019; 7:e000615.

43 Prinsen CAC, Spuls PI, Kottner J et al. Navigating the landscape of core outcome set development in dermatology. J Am Acad Dermatol 2019; 81:297–305.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

Appendix S1 Example of the search strategy.Appendix S2 Eligibility criteria.

Appendix S3 Extracted outcomes and corresponding outcome domains.